Menu
Home Explore People Places Arts History Plants & Animals Science Life & Culture Technology
On this page
Intravitreal administration

Intravitreal administration is a route of administration where a drug is injected directly into the vitreous humor of the eye, allowing localized treatment of conditions like age-related macular degeneration (AMD), diabetic retinopathy, and endophthalmitis. Compared to topical administration, it offers direct delivery by bypassing eye barriers, reducing systemic side effects common in methods such as intravenous injection. First introduced in 1911 to treat retinal detachment, intravitreal injections became standard by the 1940s for infections like endophthalmitis and cytomegalovirus retinitis. While risks such as infection exist, proper precautions lower complication rates, making it an effective eye treatment method.

Related Image Collections Add Image
Profiles
1 Image
We don't have any YouTube videos related to Intravitreal administration yet.
We don't have any PDF documents related to Intravitreal administration yet.
We don't have any Books related to Intravitreal administration yet.
We don't have any archived web articles related to Intravitreal administration yet.

Epidemiology

Intravitreal injections were proposed over a century ago however the number performed remained relatively low until the mid 2000s. Until 2001, intravitreal injections were mainly used to treat end-ophthalmitis. The number of intravitreal injections stayed fairly constant, around 4,500 injections per year in the US.9 The number of injections tripled to 15,000 in 2002 when triamcinolone injections were first used to treat diabetic macular oedema.1011 This use continued to drive an increase to 83,000 injections in 2004.12 In 2005 bevacizumab and ranibizumab intravitreal injections for the treatment of wet-AMD caused a rise in injections to 252,000.13 In 2008, over 1 million intravitreal injections were performed. This doubled to 2 million just 3 years later in 2011 when another anti-VEGF intravitreal injection aflibercept became available for the treatment of wet AMD.14 Intravitreal injections hit an all-time high in 2016 reaching over 5.9 million injections in the US.15

Uses

Intravitreal injection is used to inject a drug into the eye to reduce inflammation (anti-inflammatory), inhibit the growth and development of new blood vessels (angiostatic), or lower the permeability of blood vessels (anti-permeability), in turn curing various eye diseases.16

Disorders/diseases that can be treated with intravitreal injection include:

  • Age-related macular degeneration (AMD)/ Macular Degeneration: An eye disorder that slowly destroys sharp, central vision1718
  • Uveitis: Swelling and inflammation within the eyeball19
  • Retinal vein occlusion: A blockage of the veins that carry blood away from the retina, the back part of your eye, and out of the eye20
  • Macular edema: Swelling or thickening of the macula (the central area of the retina that provides sharp, central vision) due to abnormal fluid accumulation2122
  • Infections, such as endophthalmitis and retinitis2728
  • Noninfectious vitritis29

Sometimes, an intravitreal injection of antibiotics and steroids is given as part of routine cataract surgery. This avoids having to use drops after surgery.30

Antimicrobials

Antimicrobials are intravitreally injected to treat eye infections, such as endophthalmitis and retinitis.31 The medication used depends on the pathogen responsible for the disease.

Antibiotics

This type of drug targets on bacterial infection. The first use of intravitreal antibiotics was dated back to experiments in the 1940s, in which penicillin and sulfonamides were used to treat the rabbit endophthalmitis models.3233 Later, more studies proved the beneficial effects of intravitreal antibiotics on acute postoperative endophthalmitis.3435 In the 1970s, Peyman's research on the suggested doses for the medications was published.36 Intravitreal antibiotics then has gradually become the major treatment to manage bacterial endophthalmitis.37 Some common antibiotics administered nowadays are vancomycin (for Gram-positive bacteria) and ceftazidime (for Gram-negative bacteria).38

The dosage of antibiotics injected intravitreally is usually low to avoid possible retina toxicity.3940 Some alternative antibiotics have also been tested to replace those that have a higher risk of causing macular toxicity (e.g. aminoglycosides).4142 In light of the raised occurrence of antibiotics resistance, the medications should be chosen and evaluated with the support of bacterial culture and antibiotics sensitivity test results.43 Sometimes, combinations of different antibiotics may be needed to treat polymicrobial infections (infections that are caused by more than one type of microorganisms), or as an empirical treatment.44

Antibiotics, such as moxifloxacin, vancomycin, etc., are used perioperatively and postoperatively as a common method of endophthalmitis prevention in cataract surgery. Researches show such injection of antibiotics is more useful to prevent infection as compared to chemoprophylaxis(chemoprevention) given topically.45 However, it has recently been controversial whether it has sufficient efficacy for endophthalmitis prophylaxis, and whether it improves the effectiveness in preventing endophthalmitis by perioperative povidone-iodine when used in combination with the antiseptic.46

Antifungals

If the endophthalmitis is suspected to be a fungal infection, antifungals, such as amphotericin B and voriconazole, could be intravitreally injected to treat the disease.4748 Although amphotericin B has a broad spectrum, voriconazole is more commonly used now as it has a higher efficacy and lower toxicity.49

Antivirals

Since the 1990s, intravitreal antivirals have been used to treat cytomegalovirus retinitis (CMV retinitis) in immunodeficient patients, such as AIDS patients.5051 Some medications that could be used include ganciclovir, foscarnet, and cidofovir.5253 The amount and frequency of the intravitreal agent injected varies among the drug chosen: for example, foscarnet has to be given more frequently than ganciclovir as it has a shorter intravitreal half-life.54 If the traditional antiviral therapy fails, a combination of these two medications may be injected.55 On the other hand, antiviral drugs could also be administered for patients with acute retinal necrosis due to varicella-zoster virus retinitis.56

Anti-Vascular Endothelial Growth Factor (anti-VEGF)

The most common reason intravitreal injections are used is to administer anti-vascular endothelial growth factor (anti-VEGF) therapies to treat wet age related macular degeneration (AMD) and diabetic retinopathy.57 Both of these conditions cause damage to the retina leading to vision loss. There are three widely used Anti-VEGF drugs to treat these conditions: ranibizumab (Lucentis®; Genentech), bevacizumab (Avastin®; Genentech), and aflibercept (Eylea®; Regeneron Pharmaceuticals).58 Bevacizumab has not been FDA approved to treat wet AMD however in the US it is the first line anti-VEGF therapy for over half of ophthalmologists due to its efficacy and drastically lower cost.59  These three drugs bind to VEGF molecules preventing them from binding to VEGF receptors on the surface of endothelial cells thereby stopping the abnormal angiogenesis that causes wet AMD.  All three of these therapies have vastly improved outcomes for sufferers who had limited treatment options prior to their invention but must be administered via intravitreal injection.

Vascular endothelial growth factor (VEGF) is a type of protein the body cells produce to stimulate the growth of new blood vessels.60 Anti-VEGF agents are chemicals that could inhibit these growth factors to reduce or prevent the abnormal growth of blood vessels, which could lead to damage to the eye and vision.61

Steroids

Steroids may be administered via intravitreal injection to treat diabetic and vasculo-occlusive macular edema, exudative macular degeneration, pseudophakic cystoid macular edema, and posterior uveitis. Common steroids used to treat these conditions include dexamethasone and triamcinolone acetonide (Triescence, Alcon Laboratories, Inc.). Steroid implants, such as the dexamethasone implant (Ozurdex, Allergan, Inc.), are used for long-term treatment of macular edema. Both of these steroid work by modulating inflammatory cytokines.62

The primary use of the corticosteroids is to reduce the inflammation by inhibiting the inflammatory cytokines.63 It could be used to treat numerous eye disorders, such as diabetic retinopathy and retinal vein occlusion.6465

Below are some examples of this type of medication:

Triamcinolone acetonide

Triamcinolone acetonide is one of the most commonly used steroid agents for the treatment of several retinal conditions. The drug is often seen as an ester in commercial drugs and appears as a white- to cream-colored crystalline powder.66 It is much more soluble in alcohol than in water, which could be the reason for its longer duration of action (around 3 months after 4 mg intravitreal injection of the drug).6768 The drug is also 5 times more potent than hydrocortisone while only has a tenth of its sodium-retaining potency.69

It has proven to be effective for the management of abnormal endothelial cell proliferation-associated disorders, and the accumulation of intraretinal and subretinal fluid.70

Dexamethasone

Dexamethasone is a potent cytokine inhibitor that is naturally released from human pericytes.71 It is shown to be able to significantly decrease intercellular adhesion molecule-1 mRNA and protein levels and therefore reduce leukostasis and help maintain the blood-retinal-barrier.72 Its potency is 5 times greater than triamcinolone acetonide.73 Due to its relatively short half-life, the medication is often given as an intravitreal implant for a continuous and stable release to the target site.7475 Some newly developed dexamethasone implants, such as Ozurdex, are made from biodegradable materials that could be intravitreally injected rather than surgically implanted.7677

This corticosteroid is usually used to treat disorders and diseases including macular edema secondary to retinal vein occlusion, pseudophakic cystoid macular edema, macular edema secondary to uveitis, diabetic macular edema, and age-related macular degeneration.78

Fluocinolone acetonide

Fluocinolone acetonide is a synthetic corticosteroid as potent as dexamethasone, but with a much lower water solubility, which could be accounted for the extended period of release from the intravitreal implant injected.79 It was also proven to have a localized effect in the posterior segment of the eye and is not absorbed into the systemic circulation, thus less likely to give rise to systemic adverse effect.80

The medication could be used in treatment for noninfectious posterior uveitis and diabetic macular edema, while applications in the management of other ophthalmic diseases are still under research.818283

Gene therapy drugs

Intravitreal gene therapy is a technique for treating retinal diseases by delivering therapeutic genes directly into the eye’s vitreous humor using a viral vector, typically an adeno-associated virus (AAV).84 This approach enables retinal cells to produce beneficial proteins, potentially offering long-term or permanent treatment for conditions such as wet age-related macular degeneration (AMD), diabetic macular edema, and inherited retinal dystrophies while reducing the need for frequent injections.85 Gene therapy drugs such as lenadogene nolparvovec (Lumevoq) for Leber's hereditary optic neuropathy are examples of gene therapies delivered intravitreally.86 These are essentially recombinant viral vectors, containing the gene required for the therapy.87

Adverse events and complications

Endophthalmitis, or a bacterial infection within the eye causing inflammation of the sclera, is one of the most severe complications due to intravitreal injections. Incidence of endophthalmitis after intravitreal injection per patient has been reported to range from 0.019 to 1.6%.88 Endophthalmitis can also result in white or yellow discharge inside the eyelid, and a white, cloudy cornea. A layer of white blood cells called hypopyon may develop between the iris and the cornea. Endophthalmitis is considered an ophthalmological emergency and requires immediate treatment in many cases. It is treated with injections of antibiotics and antifungal compounds as appropriate. In severe cases a vitrectomy, or removal of vitreous humor, may be required to surgically remove infectious debris.89

Another complication of intravitreal medication administration is inflammation. Intraocular inflammation is one of the main causes of temporary pain and vision loss after an intravitreal injection. Severe inflammation can cause permanent damage to the eye. The risk of inflammation varies based on the specific drug being administered. One clinical trial of ranibizumab for age-related macular degeneration administered intravitreally reported intraocular inflammation rates between 1.4% and 2.9%. Bevacizumab, another medication for the same purpose, resulted in an incidence between 0.09% and 0.4%.90

Rhegmatogenous retinal detachment, when the retina breaks allowing vitreous fluid to leak into the subretinal space, resulting from intravitreal injection is rare, occurring at most in 0.67% of people.91 This fluid can cause sensory tissues to detach from the retina, thus losing their source of nutrition, and slowly killing the cells.92

Subconjunctival hemorrhage is the most common type of hemorrhage following intravitreal injection with a reported incidence of nearly 10% of injections. People taking aspirin may be at higher risk for hemorrhage after intravitreal injection. Choroidal hemorrhage and subretinal hemorrhage are less common than subconjunctival hemorrhage, but both have been reported to occur following intravitreal injection.93

At least one study has noted that up to 8.6% of intravitreal injections may be administered in the incorrect eye. Factors identified by Mimouni et al. in 2020 which may lead to a person identifying the wrong eye for self-administration include length of time since last injection and previous injections in both eyes.94

Side effects of intravitreal injection can be classified into two categories: drug-related side effects and injection-related side effects.95 For example, in an intravitreal steroid injection, complications could be divided into steroid-related adverse effects and injection-related adverse effects, in which the former most commonly include cataract formation and increase in intraocular pressure (IOP).96

Other examples of potential adverse effects are listed as follows:

  • Discomfort and pain in the injection sites97
  • Bleeding (e.g. subconjunctival, vitreous or retinal hemorrhage)98
  • Vitreous reflux (the reflux of fluid from the vitreous cavity, which contains a mixture of vitreous humor and the drug administered)99
  • Floaters (black/grey spots, small shapes or string in vision)100
  • Infectious endophthalmitis101
  • Pseudoendophthalmitis102
  • Ocular hypertension, i.e. increase in intraocular pressure (IOP)103
  • Cataract (when the needle accidentally hits the lens), or other damage to lens104
  • Rhegmatogenous retinal detachment105
  • Toxic effects of medication106

A surgery may be required to treat certain severe complications. Some of the above complications could also lead to blindness, or even loss of the eye (in the case of a severe infection).107

Precautions

Precautions should be taken before, during, and after the injection to lower the chances of complications, particularly infection prevention:

Pre-treatment

  • Topical antiseptic usage is important to aid in preventing potential bacterial infections.108 Common antiseptics used in practice include povidone-iodine (primarily for reducing the risk of endophthalmitis) and chlorhexidine (predominantly to counteract adverse effects caused by povidone-iodine in the aqueous form but also for those with iodine allergy or sensitivity).109
  • Pre-injection antibiotics might be given to support the topical antiseptic in preventing potential bacterial infections.110
  • Hand sterilization to significantly reduce microorganisms present on the hands of the physician prior to the injection.111
  • Sterile gloves should be used in combination with the aforementioned hand washing for the same reasons.112113
  • Collection of comprehensive information of the patient on health problems, allergies, bleeding tendencies, and medicines taken (including any over-the-counter medicines) to avoid preventable complications.114

During the injection

  • Masks, drapes, and silence (i.e. the physician and others near the patient should not talk) in order to minimize contamination through the air resulting from respiratory or nasal droplets.115

Post-treatment

  • Post-injection antibiotics may given to prevent potential bacterial infection, but are usually not included in standard procedures of intravitreal injection. Some studies show that such practice has no statistically significant benefit in preventing endophthalmitis, whereas other studies indicate that doing so can increase chances of conjunctival bacterial resistance.116117118
  • Rubbing of eyes and swimming should be avoided for several days after the injection.119
  • Eye pain or discomfort, redness, light sensitivity or changes in vision should be reported to the physician that performed the intravitreal injection.120

Procedure and guidelines

In 2004 with the rise of intravitreal injections, a group of experts established the first general guidelines for administering intravitreal injections. Until an update in 2014 these were consensus guidelines in the US. In 2014 a panel of 16 health professionals with expertise in different aspects of the injection reviewed and revised the original guidelines. Together they released areas of general agreement, areas with no clear consensus, and recommended sequence of steps for intravitreal injection.121

Changes from 2004 Guidance

Dropped Recommendations from 2004

Use of a lid speculum is no longer essential. Now a lid speculum, manual lid retraction or a similar maneuver can be used to keep the eyelids out of the way during the procedure.

The strong 2004 consensus that the pupil should be routinely dilated to examine the posterior segment of the eye post injection was dropped. Some of the 2014 panelists did not dilate the pupil for routine injections while others found this examination to be highly important. As no consensus was reached this recommendation was dropped from the 2014 guidance.

New Recommendations in 2014

In 2004 the committee did not come to a consensus on routine use of pre-, peri- or postinjection antibiotics. Since then evidence has emerged suggesting that peri-injection antibiotics do not meaningfully lower the risk of post-injection infection and periodic multi-day administration of topical ophthalmic antibiotics facilitates the colonization of drug-resistant bacteria.122123124125126127 For these reasons in 2014 the committee decided against recommending routine antibiotics.

The new guidelines include hand washing and glove use consistent with the modern-day medical practice of universal precautions. Although the use of gloves was agreed upon by the committee some panelists cited studies showing no impact of glove use on endophthalmitis rate.128129

In 2004, the topic of droplet contamination was not addressed. Since then new evidence has come to light showing that streptococcal species cause a disproportionate number of post intravitreal injection endophthalmitis cases compared to other forms of ocular surgery.130131 This is likely due to aerosolized droplet contamination from either the practitioners' or patients' mouth.132 The 2014 guidelines were updated to address these findings recommending both clinicians and patients wear face masks during the procedure.

The new guidelines recommend monitoring intraocular pressure both pre- and post-injection. This recommendation stemmed from new evidence showing that routine intravitreal administration of anti-VEGF therapies may increase intraocular pressure for a sustained time period.133

The 2014 guidelines addressed bilateral injections done in the same visit. The committee recommended treating each eye as a separate procedure and use different lots or batches of medication whenever possible. The panel was not able to support the use of sterile drapes in the procedure as retrospective studies showed no increased rate of endophthalmitis in injections done without drapes.134

Injection site

The injection is usually done at the inferotemporal quadrant (i.e. the lower quadrant away from the nose) of the eye undergoing the procedure, as it is usually more accessible.135136 However, depending on the eye's condition, patient's and the ophthalmologist's preference, other regions could also be used.137138

Patient with aphakic (without lens due to cataract surgery), or pseudophakic eye (with implanted lens after removal of natural lens) would have the injection 3.0-3.5 mm posterior to the limbus, while injection to the phakic eye (with natural lens) is done 3.5-4.0 mm posterior to the limbus.139

Location

Like many injections, intravitreal injection is commonly performed in the office setting.140141 An operation room may be a better option to provide a more sterile environment for the procedure to lower the chance of infections, yet it will also increase the costs.142 Since the occurrence of serious post-injection infection (e.g. endophthalmitis) is low, in-office intravitreal injection is preferred.143144

Steps

The exact procedures and techniques of the intravitreal injection varies among different guidelines, and may depend on the practices of the person performing the injection. Below is an example of the steps for the injection:

The patient usually leans back on the chair (in supine position), in which the headrest is stable and the patient is comfortable.145146 Sterile drape is sometimes used to cover the face of the patient and only show the eye for the injection.147148

The specialist first applies anesthetics to the eye and eyelid to numb the area, so that the patient will not feel the pain during the procedure.149150151 The type of anesthetic used depends on the practitioner practices and the patient's history. Some common forms of anesthetic used are eye drops (e.g. tetracaine/proparacaine) or gel (e.g. lidocaine 2% or 4% jelly), which is applied topically.152153 Other choices of anesthesia include the use of lidocaine soaked pledget (a small cotton or wool pad) and subconjunctival injection (injection under the conjunctiva) of anesthetic agents.154 However, the latter may cause a raised chance of subconjunctival hemorrhage.155 Sometimes, for an eye with inflammation, a retrobulbar block may be given, but usually the topical or subconjunctival anesthesia is sufficient.156 The anesthetic takes time to show the numbing effect, ranging from 1–5 minutes, depending on the chemical chosen.157

The specialist then sterilizes the eye and the surrounding area, often with povidone-iodine (PVP-I) solution, to prevent any infection in the injected site.158159 Aqueous chlorhexidine is used instead in case of adverse effects to povidone-iodine.160

Next, an eyelid speculum is placed to retract the eyelids and thus hold the eye open.161162 It helps to prevent contamination of the needle and the injection site by the eyelid or eyelashes.163 Povidone-iodine solution is applied to the conjunctiva at the site of injection.164 Another dose of local anesthetic may be given to the conjunctival surface again (for example, by placing a cotton swab soaked with the anesthetic drug solution over the targeted region), which is followed by the reapplication of PVP-I solution.165

The injection site is measured and marked with a measuring caliper or other devices.166167 The patient is then told to look away from the injection site to show the quadrant to be injected, and the doctor inserts the needle at the target site in a single motion into the mid-vitreous cavity.168 Once the needle is in the vitreous cavity, the doctor pushes the plunger to release the drug into the cavity.169 After that, the needle is removed, and the injection site is immediately covered with a cotton swab to avoid vitreous reflux (reflux of fluid from the vitreous cavity).170171 The excess PVP-I solution is rinsed away.172

Finally, the doctor checks the patient's vision and intraocular pressure (IOP) of the eye.173 The injection of certain medications, such as triamcinolone acetonide (Kenalog or Triesence), may cause a sudden increase in the IOP,174175 and the patient should be monitored until the pressure returns to a normal level. If a large volume of drug is injected, paracentesis may be required.176

Repeated injections

Treatments administered via intravitreal injection are not cures and therefore repeated injections are necessary for managing conditions. For example, anti-VEGF therapies must be injected monthly or bi-monthly for the rest of their lives in order to treat wet age related macular degeneration. A growing body of evidence has shown repeat intravitreal injections have their own increased risks and complications.

A 3x rise in intraocular pressure after an intravitreal injection is expected and usually only lasts a few minutes.177 Studies have shown an increased risk of sustained elevated intraocular pressure due to repeated intravitreal injections.178 Elevated intraocular pressure leads to tissue damage, this is how glaucoma damages the eye. Many theories as to why this is have been postulated however many focus on the effect of the repeated eye trauma. The risk of elevated intraocular pressure is so great that it is recommended clinicians monitor intraocular pressure before and after intravitreal injection.179 Mount Sinai researchers have developed a method to measure retina damage from long term intravitreal injection using optimal coherence tomography angiography (OCTA). OCTA captures the motion of red blood cells in blood vessels noninvasively allowing researchers to measure blood flow in the macula and optic nerve. From this data they were able to show areas of cumulative damage.

Potential alternatives

Intravitreal injections have vastly improved outcomes for patients with retinal diseases however the risk and patient burden associated with repeated injections has prompted researchers to pursue less invasive methods of application. There has been significant emphasis on finding methods to administer treatments topically over the last 50 years.180 This research has garnered more attention thanks to the increase in intravitreal injections and the growing evidence linking repeat injections to adverse events.

History

Intravitreal injection was first mentioned in a study in 1911, in which the injection of air was used to repair a detached retina.181182183 There were also investigations evaluating intravitreal antibiotics injection using sulfanilamide and penicillin to treat endophthalmitis in the 1940s, yet due to the inconsistency of results and safety concerns, this form of drug delivery was only for experimental use and not applied in patients.184 It was until 1998, that fomivirsen (Vitravene™), the first intravitreal administered medication, was approved by the U.S. Food and Drug Administration (FDA).185

In 2004, when Aiello et al. published the first guidelines for intravitreal injection in the journal 'Retina', fomivirsen was still the only medication licensed by the FDA for intravitreal injection.186 At the end of the year, on December 17, the first intravitreal anti-VEGF drug pegaptanib (Macugen) was also licensed by FDA for treatment of wet age-related macular degeneration (wet AMD).187188

Intravitreal injection has then become more common and a surge in the number of injections performed could be seen.189 Six extra medications, namely triamcinolone acetonide, ranibizumab (Lucentis), aflibercept (Eylea/Zaltrap), dexamethasone, ocriplasmin and fluocinolone acetonide were approved for this injection by the end of 2014.190 There are also increasing off-label use of bevacizumab (Avastin) for the management of various ophthalmologic diseases, like AMD, retinal vein occlusion and diabetic macular edema.191192 On top of that, the number of intravitreal injections has escalated from less than 3000 per year in 1999, to an estimation of near 6 million in 2016.193194

See also

References

  1. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  2. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  3. "Intravitreal Injections and Endophthalmitis". Medscape. Retrieved 2020-04-21. http://www.medscape.com/viewarticle/842379 ↩

  4. Cholkar, Kishore; Dasari, Supriya Reddy; Pal, Dhananjay; Mitra, Ashim K. (2013), "Eye: anatomy, physiology and barriers to drug delivery", Ocular Transporters and Receptors, Elsevier, pp. 1–36, doi:10.1533/9781908818317.1, ISBN 978-1-907568-86-2 978-1-907568-86-2 ↩

  5. "Intravitreal Injections and Endophthalmitis". Medscape. Retrieved 2020-04-21. http://www.medscape.com/viewarticle/842379 ↩

  6. "INTRAVITREAL INJECTIONS INFORMATION | Eye Associates". Retrieved 2020-04-23. http://www.eyeassociates.com.au/intravitreal-injections-information/ ↩

  7. Artunay, O.; Yuzbasioglu, E.; Rasier, R.; Sengül, A.; Bahcecioglu, H. (2009-02-13). "Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection". Eye. 23 (12): 2187–2193. doi:10.1038/eye.2009.7. ISSN 1476-5454. PMID 19218994. https://doi.org/10.1038%2Feye.2009.7 ↩

  8. Grzybowski, Andrzej; Told, Reinhard; Sacu, Stefan; Bandello, Francesco; Moisseiev, Elad; Loewenstein, Anat; Schmidt-Erfurth, Ursula (May 2018). "2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations". Ophthalmologica. Ophthalmologica 239 (4). 239 (4): 181–193. doi:10.1159/000486145. PMID 29393226. Retrieved 2020-05-02. https://www.karger.com/Article/FullText/486145#ref3 ↩

  9. George A. Williams. "IVT Injections: Health Policy Implications". Review of Ophthalmology. Retrieved 2020-05-02. https://www.reviewofophthalmology.com/article/ivt-injections-health-policy-implications ↩

  10. George A. Williams. "IVT Injections: Health Policy Implications". Review of Ophthalmology. Retrieved 2020-05-02. https://www.reviewofophthalmology.com/article/ivt-injections-health-policy-implications ↩

  11. "The Use of Intravitreal Triamcinolone Acetonide – An Overview". European Ophthalmic Review. 2011-01-25. Retrieved 2020-05-02. https://www.touchophthalmology.com/the-use-of-intravitreal-triamcinolone-acetonide-an-overview/ ↩

  12. George A. Williams. "IVT Injections: Health Policy Implications". Review of Ophthalmology. Retrieved 2020-05-02. https://www.reviewofophthalmology.com/article/ivt-injections-health-policy-implications ↩

  13. George A. Williams. "IVT Injections: Health Policy Implications". Review of Ophthalmology. Retrieved 2020-05-02. https://www.reviewofophthalmology.com/article/ivt-injections-health-policy-implications ↩

  14. George A. Williams. "IVT Injections: Health Policy Implications". Review of Ophthalmology. Retrieved 2020-05-02. https://www.reviewofophthalmology.com/article/ivt-injections-health-policy-implications ↩

  15. Grzybowski, Andrzej; Told, Reinhard; Sacu, Stefan; Bandello, Francesco; Moisseiev, Elad; Loewenstein, Anat; Schmidt-Erfurth, Ursula (May 2018). "2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations". Ophthalmologica. Ophthalmologica 239 (4). 239 (4): 181–193. doi:10.1159/000486145. PMID 29393226. Retrieved 2020-05-02. https://www.karger.com/Article/FullText/486145#ref3 ↩

  16. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  17. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  18. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  19. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  20. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  21. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  22. "Macular Edema | National Eye Institute". www.nei.nih.gov. Retrieved 2020-04-06. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/macular-edema ↩

  23. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  24. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  25. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  26. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  27. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  28. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  29. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  30. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  31. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  32. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  33. Radhika, Medikonda; Mithal, Kopal; Bawdekar, Abhishek; Dave, Vivek; Jindal, Animesh; Relhan, Nidhi; Albini, Thomas; Pathengay, Avinash; Flynn, Harry W (December 2014). "Pharmacokinetics of intravitreal antibiotics in endophthalmitis". Journal of Ophthalmic Inflammation and Infection. 4 (1): 22. doi:10.1186/s12348-014-0022-z. ISSN 1869-5760. PMC 4306439. PMID 25667683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306439 ↩

  34. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  35. Radhika, Medikonda; Mithal, Kopal; Bawdekar, Abhishek; Dave, Vivek; Jindal, Animesh; Relhan, Nidhi; Albini, Thomas; Pathengay, Avinash; Flynn, Harry W (December 2014). "Pharmacokinetics of intravitreal antibiotics in endophthalmitis". Journal of Ophthalmic Inflammation and Infection. 4 (1): 22. doi:10.1186/s12348-014-0022-z. ISSN 1869-5760. PMC 4306439. PMID 25667683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306439 ↩

  36. Radhika, Medikonda; Mithal, Kopal; Bawdekar, Abhishek; Dave, Vivek; Jindal, Animesh; Relhan, Nidhi; Albini, Thomas; Pathengay, Avinash; Flynn, Harry W (December 2014). "Pharmacokinetics of intravitreal antibiotics in endophthalmitis". Journal of Ophthalmic Inflammation and Infection. 4 (1): 22. doi:10.1186/s12348-014-0022-z. ISSN 1869-5760. PMC 4306439. PMID 25667683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306439 ↩

  37. Radhika, Medikonda; Mithal, Kopal; Bawdekar, Abhishek; Dave, Vivek; Jindal, Animesh; Relhan, Nidhi; Albini, Thomas; Pathengay, Avinash; Flynn, Harry W (December 2014). "Pharmacokinetics of intravitreal antibiotics in endophthalmitis". Journal of Ophthalmic Inflammation and Infection. 4 (1): 22. doi:10.1186/s12348-014-0022-z. ISSN 1869-5760. PMC 4306439. PMID 25667683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306439 ↩

  38. Cornut, P.-L.; Chiquet, C. (October 2008). "Injections intravitréennes d'antibiotiques et endophtalmies". Journal Français d'Ophtalmologie (in French). 31 (8): 815–823. doi:10.1016/S0181-5512(08)74405-X. PMID 19107050. /wiki/Doi_(identifier) ↩

  39. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  40. Radhika, Medikonda; Mithal, Kopal; Bawdekar, Abhishek; Dave, Vivek; Jindal, Animesh; Relhan, Nidhi; Albini, Thomas; Pathengay, Avinash; Flynn, Harry W (December 2014). "Pharmacokinetics of intravitreal antibiotics in endophthalmitis". Journal of Ophthalmic Inflammation and Infection. 4 (1): 22. doi:10.1186/s12348-014-0022-z. ISSN 1869-5760. PMC 4306439. PMID 25667683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306439 ↩

  41. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  42. Radhika, Medikonda; Mithal, Kopal; Bawdekar, Abhishek; Dave, Vivek; Jindal, Animesh; Relhan, Nidhi; Albini, Thomas; Pathengay, Avinash; Flynn, Harry W (December 2014). "Pharmacokinetics of intravitreal antibiotics in endophthalmitis". Journal of Ophthalmic Inflammation and Infection. 4 (1): 22. doi:10.1186/s12348-014-0022-z. ISSN 1869-5760. PMC 4306439. PMID 25667683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306439 ↩

  43. Radhika, Medikonda; Mithal, Kopal; Bawdekar, Abhishek; Dave, Vivek; Jindal, Animesh; Relhan, Nidhi; Albini, Thomas; Pathengay, Avinash; Flynn, Harry W (December 2014). "Pharmacokinetics of intravitreal antibiotics in endophthalmitis". Journal of Ophthalmic Inflammation and Infection. 4 (1): 22. doi:10.1186/s12348-014-0022-z. ISSN 1869-5760. PMC 4306439. PMID 25667683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306439 ↩

  44. Radhika, Medikonda; Mithal, Kopal; Bawdekar, Abhishek; Dave, Vivek; Jindal, Animesh; Relhan, Nidhi; Albini, Thomas; Pathengay, Avinash; Flynn, Harry W (December 2014). "Pharmacokinetics of intravitreal antibiotics in endophthalmitis". Journal of Ophthalmic Inflammation and Infection. 4 (1): 22. doi:10.1186/s12348-014-0022-z. ISSN 1869-5760. PMC 4306439. PMID 25667683. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306439 ↩

  45. Kindle, Trevor; Ferguson, Tanner; Ibach, Mitch; Greenwood, Michael; Schweitzer, Justin; Swan, Russell; Sudhagoni, Ramu G.; Berdahl, John P. (January 2018). "Safety and efficacy of intravitreal injection of steroid and antibiotics in the setting of cataract surgery and trabecular microbypass stent". Journal of Cataract & Refractive Surgery. 44 (1): 56–62. doi:10.1016/j.jcrs.2017.10.040. ISSN 0886-3350. PMID 29502618. /wiki/Doi_(identifier) ↩

  46. Kindle, Trevor; Ferguson, Tanner; Ibach, Mitch; Greenwood, Michael; Schweitzer, Justin; Swan, Russell; Sudhagoni, Ramu G.; Berdahl, John P. (January 2018). "Safety and efficacy of intravitreal injection of steroid and antibiotics in the setting of cataract surgery and trabecular microbypass stent". Journal of Cataract & Refractive Surgery. 44 (1): 56–62. doi:10.1016/j.jcrs.2017.10.040. ISSN 0886-3350. PMID 29502618. /wiki/Doi_(identifier) ↩

  47. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  48. Maryann Scholl; Justin D. Scholl. "Treatment of Endophthalmitis Resulting From Traumatic Eye Injury". www.uspharmacist.com. Retrieved 2020-04-25. https://www.uspharmacist.com/article/treatment-of-endophthalmitis-resulting-from-traumatic-eye-injury ↩

  49. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  50. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  51. "Inflammatory Retinal Diseases. Medical information". patient.info. Retrieved 2020-04-25. https://patient.info/doctor/inflammatory-retinal-diseases ↩

  52. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  53. "Cytomegalovirus Adult and Adolescent Opportunistic Infection". AIDSinfo. Archived from the original on 2020-08-31. Retrieved 2020-04-25. https://web.archive.org/web/20200831231149/https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/337/cytomegalovirus ↩

  54. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  55. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  56. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  57. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  58. Fagan, Xavier J; Al-Qureshi, Salmaan (2013). "Intravitreal injections: a review of the evidence for best practice: Intravitreal injections: evidence for best practice". Clinical & Experimental Ophthalmology. 41 (5): 500–507. doi:10.1111/ceo.12026. PMID 23078366. https://doi.org/10.1111%2Fceo.12026 ↩

  59. "Comparison of Anti-VEGF Treatments for Wet AMD". American Academy of Ophthalmology. 2020-02-03. Retrieved 2020-05-03. https://www.aao.org/eye-health/diseases/avastin-eylea-lucentis-difference ↩

  60. "Vascular Endothelial Growth Factor - Health Encyclopedia - University of Rochester Medical Center". www.urmc.rochester.edu. Retrieved 2020-04-25. https://www.urmc.rochester.edu/encyclopedia/content.aspx?ContentTypeID=167&ContentID=vegf ↩

  61. "Anti-VEGF Treatments". American Academy of Ophthalmology. 2019-03-02. Retrieved 2020-04-25. https://www.aao.org/eye-health/drugs/anti-vegf-treatments ↩

  62. Sides Media, www sidesmedia com. "Retina Today - Use of Intravitreal Steroids in the Clinic". Retina Today. Retrieved 2020-05-03. http://retinatoday.com/2010/06/supplement/use-of-intravitreal-steroids-in-the-clinic/ ↩

  63. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  64. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  65. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  66. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  67. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  68. Sides Media, www sidesmedia com. "Retina Today - Dexamethasone Intravitreal Implant: Pharmacology and Clinical Update". Retina Today. Archived from the original on 2019-02-24. Retrieved 2020-04-26. https://web.archive.org/web/20190224164843/http://retinatoday.com/2015/09/dexamethasone-intravitreal-implant-pharmacology-and-clinical-update ↩

  69. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  70. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  71. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  72. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  73. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  74. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  75. Lambiase, A.; Abdolrahimzadeh, S.; Solmaz, S.M. (2014). "An update on intravitreal implants in use for eye disorders". Drugs of Today. 50 (3): 239–49. doi:10.1358/dot.2014.050.03.2103755. ISSN 1699-3993. PMID 24696869. /wiki/Doi_(identifier) ↩

  76. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  77. Christoforidis, John B.; Chang, Susie; Jiang, Angela; Wang, Jillian; Cebulla, Colleen M. (2012). "Intravitreal Devices for the Treatment of Vitreous Inflammation". Mediators of Inflammation. 2012: 126463. doi:10.1155/2012/126463. ISSN 0962-9351. PMC 3441042. PMID 22988344. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3441042 ↩

  78. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  79. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  80. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  81. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  82. Syed, Yahiya Y. (April 2017). "Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN®): A Review in Diabetic Macular Edema". Drugs. 77 (5): 575–583. doi:10.1007/s40265-017-0722-4. ISSN 0012-6667. PMID 28283896. S2CID 42529291. /wiki/Doi_(identifier) ↩

  83. "Retisert - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 2020-04-26. https://www.drugs.com/pro/retisert.html ↩

  84. Trincão-Marques, José; Ayton, Lauren N.; Hickey, Doron G.; Marques-Neves, Carlos; Guymer, Robyn H.; Edwards, Thomas L.; Sousa, David Cordeiro (2024-09-01). "Gene and cell therapy for age-related macular degeneration: A review". Survey of Ophthalmology. 69 (5): 665–676. doi:10.1016/j.survophthal.2024.05.002. ISSN 0039-6257. https://www.sciencedirect.com/science/article/pii/S0039625724000493 ↩

  85. Ofri, Ron; Ross, Maya (2021). "The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery". Neural Regeneration Research. 16 (9): 1751. doi:10.4103/1673-5374.306063. ISSN 1673-5374. PMC 8328774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8328774 ↩

  86. Newman, Nancy J.; Yu-Wai-Man, Patrick; Carelli, Valerio; Moster, Mark L.; Biousse, Valerie; Vignal-Clermont, Catherine; Sergott, Robert C.; Klopstock, Thomas; Sadun, Alfredo A.; Barboni, Piero; DeBusk, Adam A.; Girmens, Jean François; Rudolph, Günther; Karanjia, Rustum; Taiel, Magali (2021-05-01). "Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset". Ophthalmology. 128 (5): 649–660. doi:10.1016/j.ophtha.2020.12.012. ISSN 0161-6420. https://www.sciencedirect.com/science/article/pii/S0161642020311878 ↩

  87. Vignal-Clermont C, Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Subramanian PS, Wang AG, Donahue SP, Leroy BP, Sadun AA, Klopstock T, Sergott RC, Rebolleda Fernandez G, Chwalisz BK, Banik R, Taiel M, Roux M, Sahel JA, LHON STUDY GROUP (May 2023). "Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy". Am J Ophthalmol. 249: 108–125. doi:10.1016/j.ajo.2022.11.026. hdl:11585/916799. PMID 36496192. https://www.ajo.com/article/S0002-9394(22)00464-0/fulltext ↩

  88. Ghasemi Falavarjani, K; Nguyen, Q D (July 2013). "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature". Eye. 27 (7): 787–794. doi:10.1038/eye.2013.107. ISSN 0950-222X. PMC 3709385. PMID 23722722. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709385 ↩

  89. "Endophthalmitis - The American Society of Retina Specialists". www.asrs.org. Retrieved 2020-05-02. https://www.asrs.org/patients/retinal-diseases/29/endophthalmitis ↩

  90. Ghasemi Falavarjani, K; Nguyen, Q D (July 2013). "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature". Eye. 27 (7): 787–794. doi:10.1038/eye.2013.107. ISSN 0950-222X. PMC 3709385. PMID 23722722. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709385 ↩

  91. Ghasemi Falavarjani, K; Nguyen, Q D (July 2013). "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature". Eye. 27 (7): 787–794. doi:10.1038/eye.2013.107. ISSN 0950-222X. PMC 3709385. PMID 23722722. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709385 ↩

  92. "Retinal Detachment: The Three Types". WebMD. Retrieved 2020-05-02. https://www.webmd.com/eye-health/types-retinal-detachment ↩

  93. Ghasemi Falavarjani, K; Nguyen, Q D (July 2013). "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature". Eye. 27 (7): 787–794. doi:10.1038/eye.2013.107. ISSN 0950-222X. PMC 3709385. PMID 23722722. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709385 ↩

  94. Mimouni, M; Ben Haim, LN; Rozenberg, E; Shapira, Y; Beiran, I; Zayit-Soudry, S (18 August 2020). "Self-designation of the treated eye before intravitreal injections: prevalence and predictors of incorrect calling". Retina (Philadelphia, Pa.). 41 (5): 1005–1009. doi:10.1097/IAE.0000000000002956. PMID 32826789. S2CID 221237337. /wiki/Doi_(identifier) ↩

  95. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  96. Sarao, Valentina; Veritti, Daniele; Boscia, Francesco; Lanzetta, Paolo (8 January 2014). "Intravitreal Steroids for the Treatment of Retinal Diseases". The Scientific World Journal. 2014: 989501. doi:10.1155/2014/989501. PMC 3910383. PMID 24526927. S2CID 184726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910383 ↩

  97. "Intravitreal Injections - The American Society of Retina Specialists". www.asrs.org. Retrieved 2020-04-07. https://www.asrs.org/patients/retinal-diseases/33/intravitreal-injections ↩

  98. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  99. Brodie, Frank L.; Ruggiero, Jason; Ghodasra, Devon H.; Hui, James Z.; VanderBeek, Brian L.; Brucker, Alexander J. (July 2014). "Volume and Composition of Reflux After Intravitreal Injection". Retina. 34 (7): 1473–1476. doi:10.1097/IAE.0000000000000098. ISSN 0275-004X. PMC 4065616. PMID 24451925. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065616 ↩

  100. "Eye floaters - Symptoms and causes". Mayo Clinic. Retrieved 2020-04-07. https://www.mayoclinic.org/diseases-conditions/eye-floaters/symptoms-causes/syc-20372346 ↩

  101. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  102. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  103. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  104. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  105. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  106. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  107. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  108. "How to Give Intravitreal Injections". American Academy of Ophthalmology. 2013-04-01. Retrieved 2020-04-07. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections ↩

  109. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  110. "How to Give Intravitreal Injections". American Academy of Ophthalmology. 2013-04-01. Retrieved 2020-04-07. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections ↩

  111. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  112. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  113. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  114. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  115. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  116. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  117. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  118. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  119. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  120. "Intravitreal injection: MedlinePlus Medical Encyclopedia". medlineplus.gov. Retrieved 2020-03-26. https://medlineplus.gov/ency/article/007629.htm ↩

  121. Colin A. McCannel; Harry W. Flynn Jr.; Emmett T. Cunningham Jr. "Updated Guidelines for Intravitreal Injection". Review of Ophthalmology. Retrieved 2020-05-02. https://www.reviewofophthalmology.com/article/updated-guidelines-for-intravitreal-injection ↩

  122. Bhavsar, Abdhish R. (2009-12-14). "Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not Required". Archives of Ophthalmology. 127 (12): 1581–3. doi:10.1001/archophthalmol.2009.304. ISSN 0003-9950. PMC 2874253. PMID 20008710. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874253 ↩

  123. Stockdale, Cynthia R. (2012-06-01). "Update on Risk of Endophthalmitis After Intravitreal Drug Injections and Potential Impact of Elimination of Topical Antibiotics". Archives of Ophthalmology. 130 (6): 809–10. doi:10.1001/archophthalmol.2012.227. ISSN 0003-9950. PMC 3489025. PMID 22801859. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489025 ↩

  124. Storey, Philip; Dollin, Michael; Pitcher, John; Reddy, Sahitya; Vojtko, Joseph; Vander, James; Hsu, Jason; Garg, Sunir J. (January 2014). "The Role of Topical Antibiotic Prophylaxis to Prevent Endophthalmitis after Intravitreal Injection". Ophthalmology. 121 (1): 283–289. doi:10.1016/j.ophtha.2013.08.037. ISSN 0161-6420. PMID 24144453. /wiki/Doi_(identifier) ↩

  125. Cheung, Crystal S.Y.; Wong, Amanda W.T.; Lui, Alex; Kertes, Peter J.; Devenyi, Robert G.; Lam, Wai-Ching (August 2012). "Incidence of Endophthalmitis and Use of Antibiotic Prophylaxis after Intravitreal Injections". Ophthalmology. 119 (8): 1609–1614. doi:10.1016/j.ophtha.2012.02.014. ISSN 0161-6420. PMID 22480743. /wiki/Doi_(identifier) ↩

  126. Bhatt, Shabari S; Stepien, Kimberly E; Joshi, Komal (November 2011). "Prophylactic Antibiotic Use After Intravitreal Injection". Retina. 31 (10): 2032–2036. doi:10.1097/iae.0b013e31820f4b4f. ISSN 0275-004X. PMC 4459136. PMID 21659941. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4459136 ↩

  127. Dave, Sarita B.; Toma, Hassanain S.; Kim, Stephen J. (October 2011). "Ophthalmic Antibiotic Use and Multidrug-Resistant Staphylococcus epidermidis". Ophthalmology. 118 (10): 2035–2040. doi:10.1016/j.ophtha.2011.03.017. ISSN 0161-6420. PMID 21856006. /wiki/Doi_(identifier) ↩

  128. Bhavsar, Abdhish R. (2009-12-14). "Risk of Endophthalmitis After Intravitreal Drug Injection When Topical Antibiotics Are Not Required". Archives of Ophthalmology. 127 (12): 1581–3. doi:10.1001/archophthalmol.2009.304. ISSN 0003-9950. PMC 2874253. PMID 20008710. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874253 ↩

  129. Cheung, Crystal S.Y.; Wong, Amanda W.T.; Lui, Alex; Kertes, Peter J.; Devenyi, Robert G.; Lam, Wai-Ching (August 2012). "Incidence of Endophthalmitis and Use of Antibiotic Prophylaxis after Intravitreal Injections". Ophthalmology. 119 (8): 1609–1614. doi:10.1016/j.ophtha.2012.02.014. ISSN 0161-6420. PMID 22480743. /wiki/Doi_(identifier) ↩

  130. Mccannel, Colin A (April 2011). "Meta-Analysis of Endophthalmitis After Intravitreal Injection of Anti–Vascular Endothelial Growth Factor Agents". Retina. 31 (4): 654–661. doi:10.1097/iae.0b013e31820a67e4. ISSN 0275-004X. PMID 21330939. S2CID 26057661. /wiki/Doi_(identifier) ↩

  131. Chen, Eric; Lin, Michael Y; Cox, Joel; Brown, David M (September 2011). "ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION: The Importance of Viridans Streptococci". Retina. 31 (8): 1525–1533. doi:10.1097/IAE.0b013e318221594a. ISSN 0275-004X. PMID 21878800. S2CID 39413800. /wiki/Doi_(identifier) ↩

  132. Wen, Joanne C. (2011-12-01). "Bacterial Dispersal Associated With Speech in the Setting of Intravitreous Injections". Archives of Ophthalmology. 129 (12): 1551–1554. doi:10.1001/archophthalmol.2011.227. ISSN 0003-9950. PMID 21825179. https://doi.org/10.1001%2Farchophthalmol.2011.227 ↩

  133. Choi, Daniel Y; Ortube, Maria Carolina; Mccannel, Colin A; Sarraf, David; Hubschman, Jean-Pierre; Mccannel, Tara A; Gorin, Michael B (June 2011). "Sustained Elevated Intraocular Pressures After Intravitreal Injection of Bevacizumab, Ranibizumab, and Pegaptanib". Retina. 31 (6): 1028–1035. doi:10.1097/IAE.0b013e318217ffde. ISSN 0275-004X. PMID 21836409. S2CID 20238293. /wiki/Doi_(identifier) ↩

  134. Pilli, Suman; Kotsolis, Athanasios; Spaide, Richard F.; Slakter, Jason; Freund, K. Bailey; Sorenson, John; Klancnik, James; Cooney, Michael (May 2008). "Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Injections in An Office Setting". American Journal of Ophthalmology. 145 (5): 879–882. doi:10.1016/j.ajo.2007.12.036. ISSN 0002-9394. PMID 18329624. /wiki/Richard_F._Spaide ↩

  135. "How to Give Intravitreal Injections". American Academy of Ophthalmology. 2013-04-01. Retrieved 2020-04-07. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections ↩

  136. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  137. "How to Give Intravitreal Injections". American Academy of Ophthalmology. 2013-04-01. Retrieved 2020-04-07. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections ↩

  138. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  139. "How to Give Intravitreal Injections". American Academy of Ophthalmology. 2013-04-01. Retrieved 2020-04-07. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections ↩

  140. "Intravitreal Injection Technique: a primer". www.eyerounds.org. Retrieved 2020-04-07. http://www.eyerounds.org/tutorials/intravitreal-injection/ ↩

  141. "Intravitreal Injections - The American Society of Retina Specialists". www.asrs.org. Retrieved 2020-04-07. https://www.asrs.org/patients/retinal-diseases/33/intravitreal-injections ↩

  142. "Intravitreal Injection Technique: a primer". www.eyerounds.org. Retrieved 2020-04-07. http://www.eyerounds.org/tutorials/intravitreal-injection/ ↩

  143. "Intravitreal Injection Technique: a primer". www.eyerounds.org. Retrieved 2020-04-07. http://www.eyerounds.org/tutorials/intravitreal-injection/ ↩

  144. Tabandeh, Homayoun; Boscia, Francesco; Sborgia, Alessandra; Ciracì, Lorenza; Dayani, Pouya; Mariotti, Cesare; Furino, Claudio; Flynn, Harry W. (January 2014). "ENDOPHTHALMITIS ASSOCIATED WITH INTRAVITREAL INJECTIONS: Office-Based Setting and Operating Room Setting". Retina. 34 (1): 18–23. doi:10.1097/IAE.0000000000000008. ISSN 0275-004X. PMID 24362413. S2CID 34637729. /wiki/Doi_(identifier) ↩

  145. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  146. "Intravitreal Injections - The American Society of Retina Specialists". www.asrs.org. Retrieved 2020-04-07. https://www.asrs.org/patients/retinal-diseases/33/intravitreal-injections ↩

  147. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  148. Yorston, David (2014). "Intravitreal injection technique". Community Eye Health. 27 (87): 47. ISSN 0953-6833. PMC 4322739. PMID 25918462. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322739 ↩

  149. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  150. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  151. "Intravitreal Injections - The American Society of Retina Specialists". www.asrs.org. Retrieved 2020-04-07. https://www.asrs.org/patients/retinal-diseases/33/intravitreal-injections ↩

  152. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  153. "Intravitreal Injections - The American Society of Retina Specialists". www.asrs.org. Retrieved 2020-04-07. https://www.asrs.org/patients/retinal-diseases/33/intravitreal-injections ↩

  154. Fagan, Xavier J; Al-Qureshi, Salmaan (2013). "Intravitreal injections: a review of the evidence for best practice: Intravitreal injections: evidence for best practice". Clinical & Experimental Ophthalmology. 41 (5): 500–507. doi:10.1111/ceo.12026. PMID 23078366. https://doi.org/10.1111%2Fceo.12026 ↩

  155. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  156. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  157. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  158. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  159. "Intravitreal Injections - The American Society of Retina Specialists". www.asrs.org. Retrieved 2020-04-07. https://www.asrs.org/patients/retinal-diseases/33/intravitreal-injections ↩

  160. Fagan, Xavier J; Al-Qureshi, Salmaan (2013). "Intravitreal injections: a review of the evidence for best practice: Intravitreal injections: evidence for best practice". Clinical & Experimental Ophthalmology. 41 (5): 500–507. doi:10.1111/ceo.12026. PMID 23078366. https://doi.org/10.1111%2Fceo.12026 ↩

  161. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  162. "Intravitreal Injections - The American Society of Retina Specialists". www.asrs.org. Retrieved 2020-04-07. https://www.asrs.org/patients/retinal-diseases/33/intravitreal-injections ↩

  163. Avery, Robert L.; Bakri, Sophie J.; Blumenkranz, Mark S.; Brucker, Alexander J.; Cunningham, Emmett T.; DʼAmico, Donald J.; Dugel, Pravin U.; Flynn, Harry W.; Freund, K. Bailey; Haller, Julia A.; Jumper, J. Michael (2014). "Intravitreal Injection Technique and Monitoring". Retina. 34: S1 – S18. doi:10.1097/iae.0000000000000399. ISSN 0275-004X. PMID 25489719. S2CID 205645429. /wiki/Doi_(identifier) ↩

  164. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  165. Ingrid U. Scott; Harry W. Flynn Jr. "An Update on the Intravitreal Injection Procedure". www.retina-specialist.com. Retrieved 2020-04-05. http://www.retina-specialist.com/article/an-update-on-the-intravitreal-injection-procedure ↩

  166. "How to Give Intravitreal Injections". American Academy of Ophthalmology. 2013-04-01. Retrieved 2020-04-07. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections ↩

  167. Yorston, David (2014). "Intravitreal injection technique". Community Eye Health. 27 (87): 47. ISSN 0953-6833. PMC 4322739. PMID 25918462. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322739 ↩

  168. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  169. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  170. "How to Give Intravitreal Injections". American Academy of Ophthalmology. 2013-04-01. Retrieved 2020-04-07. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections ↩

  171. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  172. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  173. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  174. "Intravitreal Kenalog Injections". American Academy of Ophthalmology. 2004-10-01. Retrieved 2020-04-06. https://www.aao.org/eyenet/article/intravitreal-kenalog-injections ↩

  175. "Trivaris Intravitreal, Triesence (triamcinolone intravitreal) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 2020-04-07. https://reference.medscape.com/drug/trivaris-intravitreal-triamcinolone-intravitreal-999656#4 ↩

  176. "Intravitreal Injections - EyeWiki". eyewiki.aao.org. Retrieved 2020-04-07. https://eyewiki.aao.org/Intravitreal_Injections ↩

  177. "Breakthrough Technology Used to Discover Eye Damage from Repeated Intravitreal Injections | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2020-05-02. https://www.mountsinai.org/about/newsroom/2020/breakthrough-technology-used-to-discover-eye-damage-from-repeated-intravitreal-injections-pr ↩

  178. Ghasemi Falavarjani, K; Nguyen, Q D (July 2013). "Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature". Eye. 27 (7): 787–794. doi:10.1038/eye.2013.107. ISSN 0950-222X. PMC 3709385. PMID 23722722. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709385 ↩

  179. Colin A. McCannel; Harry W. Flynn Jr.; Emmett T. Cunningham Jr. "Updated Guidelines for Intravitreal Injection". Review of Ophthalmology. Retrieved 2020-05-02. https://www.reviewofophthalmology.com/article/updated-guidelines-for-intravitreal-injection ↩

  180. Yellepeddi, V. K.; Palakurthi, S. (2016). "Home Organization Selection". Journal of Ocular Pharmacology and Therapeutics. 32 (2): 67–82. doi:10.1089/jop.2015.0047. PMID 26666398. Retrieved 2020-05-03. https://docs.shib.ncsu.edu/ds/ncsu/WAYF?entityID=https%3a%2f%2fprox.lib.ncsu.edu%2fezproxy%2fshibboleth&return=https%3a%2f%2flogin.prox.lib.ncsu.edu%2fShibboleth.sso%2fDS%3fSAMLDS%3d1%26target%3dezp.2aHR0cHM6Ly93d3cubGllYmVydHB1Yi5jb20vZG9pLzEwLjEwODkvam9wLjIwMTUuMDA0Nw%2d%2d ↩

  181. "How to Give Intravitreal Injections". American Academy of Ophthalmology. 2013-04-01. Retrieved 2020-04-07. https://www.aao.org/eyenet/article/how-to-give-intravitreal-injections ↩

  182. Grzybowski, Andrzej; Told, Reinhard; Sacu, Stefan; Bandello, Francesco; Moisseiev, Elad; Loewenstein, Anat; Schmidt-Erfurth, Ursula; on behalf of the Euretina Board (2018). "2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations". Ophthalmologica. 239 (4): 181–193. doi:10.1159/000486145. ISSN 0030-3755. PMID 29393226. S2CID 12528415. https://www.karger.com/Article/FullText/486145 ↩

  183. AIELLO, LLOYD P.; BRUCKER, ALEXANDER J.; CHANG, STANLEY; CUNNINGHAM, EMMETT T.; D'AMICO, DONALD J.; FLYNN, HARRY W.; GRILLONE, LISA R.; HUTCHERSON, STEVE; LIEBMANN, JEFFREY M.; O'BRIEN, TERRENCE P.; SCOTT, INGRID U. (October 2004). "Evolving Guidelines for Intravitreous Injections". Retina. 24 (Supplement): S3 – S19. doi:10.1097/00006982-200410001-00002. ISSN 0275-004X. PMID 15483476. S2CID 23532836. /wiki/Doi_(identifier) ↩

  184. AIELLO, LLOYD P.; BRUCKER, ALEXANDER J.; CHANG, STANLEY; CUNNINGHAM, EMMETT T.; D'AMICO, DONALD J.; FLYNN, HARRY W.; GRILLONE, LISA R.; HUTCHERSON, STEVE; LIEBMANN, JEFFREY M.; O'BRIEN, TERRENCE P.; SCOTT, INGRID U. (October 2004). "Evolving Guidelines for Intravitreous Injections". Retina. 24 (Supplement): S3 – S19. doi:10.1097/00006982-200410001-00002. ISSN 0275-004X. PMID 15483476. S2CID 23532836. /wiki/Doi_(identifier) ↩

  185. AIELLO, LLOYD P.; BRUCKER, ALEXANDER J.; CHANG, STANLEY; CUNNINGHAM, EMMETT T.; D'AMICO, DONALD J.; FLYNN, HARRY W.; GRILLONE, LISA R.; HUTCHERSON, STEVE; LIEBMANN, JEFFREY M.; O'BRIEN, TERRENCE P.; SCOTT, INGRID U. (October 2004). "Evolving Guidelines for Intravitreous Injections". Retina. 24 (Supplement): S3 – S19. doi:10.1097/00006982-200410001-00002. ISSN 0275-004X. PMID 15483476. S2CID 23532836. /wiki/Doi_(identifier) ↩

  186. AIELLO, LLOYD P.; BRUCKER, ALEXANDER J.; CHANG, STANLEY; CUNNINGHAM, EMMETT T.; D'AMICO, DONALD J.; FLYNN, HARRY W.; GRILLONE, LISA R.; HUTCHERSON, STEVE; LIEBMANN, JEFFREY M.; O'BRIEN, TERRENCE P.; SCOTT, INGRID U. (October 2004). "Evolving Guidelines for Intravitreous Injections". Retina. 24 (Supplement): S3 – S19. doi:10.1097/00006982-200410001-00002. ISSN 0275-004X. PMID 15483476. S2CID 23532836. /wiki/Doi_(identifier) ↩

  187. "Intravitreal Injections and Endophthalmitis". Medscape. Retrieved 2020-04-21. http://www.medscape.com/viewarticle/842379 ↩

  188. Colin A. McCannel; Harry W. Flynn Jr.; Emmett T. Cunningham Jr. "Updated Guidelines for Intravitreal Injection". Review of Ophthalmology. Retrieved 2020-04-21. https://www.reviewofophthalmology.com/article/updated-guidelines-for-intravitreal-injection ↩

  189. Shikari, Hasanain; Samant, PreetamM (2016). "Intravitreal injections: A review of pharmacological agents and techniques". Journal of Clinical Ophthalmology and Research. 4 (1): 51. doi:10.4103/2320-3897.174429. ISSN 2320-3897. S2CID 53481704. http://www.jcor.in/text.asp?2016/4/1/51/174429 ↩

  190. "Intravitreal Injections and Endophthalmitis". Medscape. Retrieved 2020-04-21. http://www.medscape.com/viewarticle/842379 ↩

  191. "Intravitreal Injections and Endophthalmitis". Medscape. Retrieved 2020-04-21. http://www.medscape.com/viewarticle/842379 ↩

  192. Colin A. McCannel; Harry W. Flynn Jr.; Emmett T. Cunningham Jr. "Updated Guidelines for Intravitreal Injection". Review of Ophthalmology. Retrieved 2020-04-21. https://www.reviewofophthalmology.com/article/updated-guidelines-for-intravitreal-injection ↩

  193. "Intravitreal Injections and Endophthalmitis". Medscape. Retrieved 2020-04-21. http://www.medscape.com/viewarticle/842379 ↩

  194. Grzybowski, Andrzej; Told, Reinhard; Sacu, Stefan; Bandello, Francesco; Moisseiev, Elad; Loewenstein, Anat; Schmidt-Erfurth, Ursula; on behalf of the Euretina Board (2018). "2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations". Ophthalmologica. 239 (4): 181–193. doi:10.1159/000486145. ISSN 0030-3755. PMID 29393226. S2CID 12528415. https://www.karger.com/Article/FullText/486145 ↩